| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Dr. Morice Shares Trends and Predictions for 2025
News
The healthcare and diagnostics landscape is poised for transformative changes in 2025 driven by technological advancements and evolving market dynamics. This article explores the significant trends and developments that are likely to influence laboratory medicine, pathology, and clinical diagnostics this year.
Technological innovation will continue to accelerate with large language models and artificial intelligence (AI) in an especially rapid cycle of improvement. An increasing volume of health data, enhanced computing power, and the growing expertise of bioinformaticians and computer scientists mean this progress is expected to continue at an unprecedented pace.
With over 70% of quantitative data in electronic health records coming from clinical laboratories, these advancements will play a crucial role in transforming healthcare practices.
Digital pathology is also set to make strides in 2025 due to the expanding adoption of the technology and decreasing costs of scanning and data storage. The growing need for companion diagnostics for antibody drug conjugate therapies as well as others will drive biomarker discovery, essential for developing personalized treatment plans.
Other technologies will also become increasingly available; mass spectrometry will enhance the study of proteins and metabolites, fueling advances in clinical proteomics and metabolomics. These developments will lead to improved diagnosis and disease management, as well as new workflows to address workforce constraints and enhance speed and accuracy in healthcare.
The regulatory environment will likely remain uncertain in 2025. The diagnostics industry is particularly focused on the U.S. Food and Drug Administration’s (FDA) regulation of laboratory-developed tests. Having a new federal administration will likely impact the path forward, and a legislative solution for laboratory tests is still possible. However, significant resolutions are not expected to be a first-year priority of the new administration.
This year will likely see continued mergers and acquisitions with most being larger organizations acquiring small, single-test companies. The increasing importance of data may also influence acquisitions, with insurers, pharmaceutical companies, and other organizations potentially acquiring diagnostic companies to create direct data pipelines.
Fatigue from the pandemic response has led to some complacency in preparing for future outbreaks, making the massive investments in distributed diagnostics that some anticipated seem unlikely. However, there is a global trend toward public-private partnerships to monitor and prepare for emerging diseases and infectious outbreaks. The trend toward partnerships will likely continue.
Movement of care out of traditional healthcare settings and convenience will continue to drive the use of at-home testing and discussions about its potential.
However, options will remain limited to tests with easy-to-obtain samples. Expansion is more likely for point-of-need testing, driven by ambulatory care settings, where clinicians aim to provide quick answers and solutions in a single encounter.
In addition, telemedicine has grown amid changes in patient expectations and federal policies, but uncertainty remains about how diagnostics will integrate into this ecosystem.
Remote monitoring and wearable diagnostic solutions, such as outpatient cardiac monitoring and smartwatches, are advancing rapidly in response to this trend, but it is unlikely there will be widespread adoption of biometric signals for clinical diagnostics in the near term.
Retail companies, understanding their customers well, will likely continue to push consumerism in healthcare, with many piloting healthcare offerings.
Despite some notable failures in recent years, the concept of convenient, immediate results remains powerful, and retail organizations are expected to continue searching for a successful model. This will likely include diagnostic solutions that allow consumers to get quick answers.
The healthcare and diagnostics fields will remain dynamic in 2025 with advancements in technologies and delivery models as well as continued evolution of patient and customer expectations. These trends underscore the need for continuous adaptation and innovation while keeping the needs of the patient and society at the center of all we do. I look forward to continuing to provide insights related to industry news. You can hear more from me on the “Answers From the Lab” podcast and on LinkedIn.
